Compare PROP & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PROP | VTGN |
|---|---|---|
| Founded | 2001 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.6M | 122.1M |
| IPO Year | N/A | N/A |
| Metric | PROP | VTGN |
|---|---|---|
| Price | $1.81 | $4.27 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $6.75 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 900.1K |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $166,577,000.00 | $721,000.00 |
| Revenue This Year | $3,967.26 | $54.26 |
| Revenue Next Year | $71.16 | $478.23 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.64 | $1.90 |
| 52 Week High | $10.58 | $5.14 |
| Indicator | PROP | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 47.89 | 51.99 |
| Support Level | $1.67 | $3.36 |
| Resistance Level | $1.92 | $4.97 |
| Average True Range (ATR) | 0.11 | 0.51 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 50.91 | 54.49 |
Prairie Operating Co is a Houston-based independent energy company engaged in the development and acquisition of oil and natural gas resources in the United States. The Company's assets and operations are concentrated in the oil and liquids-rich regions of the Denver-Julesburg (DJ) Basin, with a focus on the Niobrara and Codell formations. The Company is committed to the responsible development of its oil and natural gas resources and is focused on maximizing returns through consistent growth, capital discipline, and sustainable cash flow generation.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.